Amarin has announced news long awaited by investors -- a partnership with a big pharma. Although the pharma itself is not a household name, Japan's Kowa Pharmaceuticals will essentially triple the sales force for Vascepa. Sales of the high-triglyceride fighter, Amarin's sole approved product, have disappointed, and they appear headed nowhere close to Wall Street's initial peak sales estimates.

On this edition of Market Checkup, The Motley Fool's health care-focused investing show, analysts David Williamson and Michael Douglass discuss the new marketing deal, the challenges the companies will face (including a generic threat and competition from AstraZeneca), and whether this move will presage a turnaround in Amarin's stock.

3 stocks poised to be multibaggers
The one sure way to get wealthy is to invest in a groundbreaking company that goes on to dominate a multibillion-dollar industry. Our analysts have found multibagger stocks time and again. And now they think they've done it again with three stock picks that they believe could generate the same type of phenomenal returns. They've revealed these picks in a new free report that you can download instantly by clicking here now.

David Williamson owns shares of Amarin. Michael Douglass and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.